Abeona Therapeutics Inc vs Riot Platforms Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Riot Platforms Inc trades at $20.35 (market cap $7.59B). The key difference: Riot Platforms Inc is far larger — about 18× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | RIOT | |
|---|---|---|
Market Cap | $421.19M | $7.59B |
Sector | Health | Technology |
52-Week High | $7.45 | $28.67 |
52-Week Low | $4.17 | $11.33 |
Enterprise Value | $276.10M | $8.00B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
RIOT Platforms trades at $20.835, up 7.4% on news of a transformative $9.1 billion AI infrastructure deal with Anthropic. Despite bearish technical signals and consecutive quarterly losses, the stock shows strong momentum driven by the company's strategic pivot from bitcoin mining to data center operations. Analyst sentiment remains overwhelmingly positive with 94% buy ratings and a $33.40 consensus price target, representing significant upside potential.
The outlook hinges on successful execution of the AI infrastructure strategy, though substantial risks persist including negative cash flow, widening losses, and competitive pressures. Investors face a high-risk, high-reward scenario where the massive Anthropic deal could drive long-term value if operational challenges are overcome.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →